Respira Therapeutics

Executive Summary

Respira Therapeutics is a private biopharmaceutical company focused on developing next-generation inhaled therapies for cardiopulmonary diseases. Founded in 2013 and headquartered in Albuquerque, New Mexico, the company leverages advanced particle engineering and proprietary device technologies to enhance drug delivery to the lung periphery. Its lead program targets Pulmonary Arterial Hypertension (PAH) with an 'as-needed' inhaled therapy, addressing a significant unmet need for rapid symptom relief and potentially improving patient compliance. By optimizing drug deposition and reducing systemic side effects, Respira's approach aims to differentiate from current standard-of-care treatments. The company is currently in Phase 2 clinical development for its PAH candidate, with a focus on demonstrating efficacy and safety in a targeted patient population. If successful, this therapy could offer a novel on-demand treatment option for PAH patients, complementing existing background therapies. While private and without disclosed financing details, Respira's innovative technology platform and clear clinical strategy position it for potential value inflection upon positive data readout. Near-term milestones include progressing the Phase 2 trial and exploring potential strategic partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for inhaled PAH therapy50% success
• Q2 2026Potential partnership or licensing deal40% success